These combined effects significantly reduce daily calorie consumption without compromising energy levels
Visvabharathy, V., MacPhedran, S., Shupp, K., & King, B
Among the 12 studies, four excluded patients with known GI motility disorders, including autonomic dysfunction 12 , 13 , 18 , 23
This warning was not included in the initial drug-warning labels of many semaglutide drugs
Combination therapy is typically considered for patients with inadequate glycemic control on GLP-1 monotherapy or when cost, adherence, or side effects favor adding an oral DPP-4 rather than increasing GLP-1 dose